We participated in the development of a new chemical entity licensed to Novartis, now in Phase III clinical trials as a novel cancer immunotherapy.
We work with academic groups, biotech companies, pharmaceutical leaders, and institutions worldwide, building long-lasting relationships that generate impact and innovation.
We participated in the development of a new chemical entity licensed to Novartis, now in Phase III clinical trials as a novel cancer immunotherapy.
In a Joint Research Unit with Laboratorios ESTEVE, we developed a new chemical entity for neuropathic pain that reached Phase III, and was later repurposed for COVID-19 with positive proof-of-concept results.
Oluptiur? Equi sumquis tempore pratur res est et ut eum estiunt ibusci non restem volorun diaecae. Ita vitis enis il mintis cones dolenda non nis.
Pinpoint your future discovery.
Talk to our scientists.
We manage the science,
tailored to your needs.
Reliable results & ongoing
support.